Did you know that over $1.6 trillion of America’s $4.9 trillion healthcare expenditure in 2023 went to hospitals? You can add up all the spending on physician and clinical services and prescription drugs, and it’s still less than we spend on hospitals.<\/p>\n
Over the past 25 years, hospitals have been learning they can retain more profit from the surgical procedures they perform if they first invest in one of Intuitive Surgical’s (NASDAQ: ISRG) da Vinci systems. Hospitals have been beating a path to Intuitive’s door to get their hands on its machines, but it isn’t the only company developing and marketing surgical robots<\/a>.<\/p>\n In 2014, Medtronic (NYSE: MDT), a giant in the medical-device arena, acquired Mazor Robotics, a company focused on spinal surgeries. More recently, it’s been developing its Hugo robot-assisted surgical (RAS) system to tackle procedures typically performed with da Vinci systems.<\/p>\n Strong uptake of da Vinci machines pushed shares of Intuitive Surgical up by about 23,300% since its initial public offering<\/a> (IPO). Here’s a look at what Medtronic’s accomplished recently to see if investors can expect similar gains on the back of the company’s Hugo systems.<\/p>\n Intuitive Surgical recently reported 10,763 of its da Vinci systems were installed as of Sept. 30, 2025. Worldwide procedures performed using da Vinci systems rose by 19% year over year during the third quarter. Lung tumor biopsies performed with its relatively new Ion system jumped 52% higher year over year.<\/p>\n System sales are significant, but Intuitive makes most of its money from sales of instruments and accessories that must be replaced before each procedure. Intuitive Surgical reported third-quarter sales that surged 23% higher year over year to an annualized $10 billion.<\/p>\n Assessing the market performance of Medtronic’s robot-assisted surgical systems isn’t easy. It lumps Mazor-related sales into its cranial and spinal technologies division. Hugo-related sales are folded into a division called surgical and endoscopy. Management still isn’t sharing many details regarding the number of systems installed or how many procedures they’re performing.<\/p>\n Story continues <\/p>\n During Medtronic’s fiscal first quarter that ended on July 25, 2025, surgical and endoscopy sales rose 4.4%, while cranial and spinal technologies revenue climbed 5.5%. Annualized sales for both divisions climbed to an annualized $11.3 billion.<\/p>\n On the surface, it may seem like Medtronic is competing well against Intuitive Surgical, but this isn’t necessarily the case. The reporting divisions that house Medtronic’s surgical robots contain many non-robotic products. If the company’s share of the surgical-robotics market was growing rapidly, it’s unlikely that management would want to keep those numbers a secret.<\/p>\n In April, Hugo met its goals in a clinical trial that tested its ability to complete urologic procedures, including prostatectomies. The results show Hugo leads to dramatically fewer complications versus old-fashioned, non-robot-assisted surgery, but this won’t necessarily lead to uptake in this arena.<\/p>\n Intuitive’s da Vinci machines perform a lot of urologic procedures, too. So far, it’s hard to say that one system is any better than the other. A recent meta-analysis of eight different studies regarding prostatectomies showed postoperative outcomes, including complications, were statistically similar for patients who were operated on by a da Vinci system or a Hugo system.<\/p>\n Intuitive Surgical’s already existing footprint is an enormous advantage that could prevent Hugo from gaining a large share of the surgical-robotics market. Hospitals that already have one surgical team trained to use a da Vinci system have a strong financial incentive to continue choosing Intuitive Surgical for subsequent systems.<\/p>\n As a leader in the medical-device industry, Medtronic benefits from economies of scale. Plus, its giant global salesforce is ready to market any medical technology it acquires from smaller start-ups, which often want to avoid hiring international sales teams.<\/p>\n Medtronic’s advantages could allow the company to continue recording steadily growing profits for decades to come. That said, I don’t expect its Hugo systems to overcome Intuitive’s head start when it comes to prostatectomies and related procedures.<\/p>\n Before you buy stock in Medtronic, consider this:<\/p>\n The Motley Fool Stock Advisor analyst team just identified what they believe are the\u00a010 best stocks<\/a> for investors to buy now\u2026 and Medtronic wasn\u2019t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.<\/p>\n Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation,\u00a0you\u2019d have $669,449!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you\u2019d have $1,110,486!*<\/p>\n Now, it\u2019s worth noting\u00a0Stock Advisor\u2019s total average return is 1,076% \u2014 a market-crushing outperformance compared to 191% for the S&P 500.\u00a0Don’t miss the latest top 10 list, available with\u00a0Stock Advisor, and join an investing community built by individual investors for individual investors.<\/p>\n See the 10 stocks \u00bb<\/a><\/p>\n *Stock Advisor returns as of October 20, 2025<\/p>\n Cory Renauer<\/a> has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Intuitive Surgical. The Motley Fool recommends Medtronic and recommends the following options: long January 2026 $75 calls on Medtronic and short January 2026 $85 calls on Medtronic. The Motley Fool has a disclosure policy<\/a>.<\/p>\n Image source: Getty Images. <\/p>\n